ASX: ADO

AnteoTech

ANTEOTECH COMPLETES INITIAL CLIA DEVELOPMENT PROGRAM AND ADVANCES COMMERCIAL RELATIONSHIP

BRISBANE, AUSTRALIA, 1 July 2026: AnteoTech Ltd (ASX: ADO) ('AnteoTech' or 'the Company') is pleased to announce:

Key points:

- **The initial stage of a collaborative immunoassay product development work program that commenced in March 2026[1], has been successfully completed on schedule. This program is focused on the development of AnteoBind™ NXT activated magnetic particles for the global chemiluminescent immunoassay (CLIA) market. The next stage of work has been agreed and is about to commence.**
- **The Initial Work Program involved performance testing of AnteoBind™ NXT activated magnetic particles supplied by a large global life sciences company for their suitability for use in large scale, high-throughput, automated CLIA diagnostic platforms.**
- **AnteoBind™ NXT significantly enhances CLIA assay sensitivity while reducing raw material consumption and lowering assay production costs by delivering uniform, oriented antibody alignment on magnetic particles,**
- **Activated magnetic particles play a critical role in delivering the performance required by today's high throughput, fully automated CLIA platforms used in clinical laboratories worldwide.**
- **Revenue of A$61,595 from this program has been recognised in FY2026.**
- **In March 2026, AnteoTech released a CLIA White Paper outlining broader AnteoBind™ NXT magnetic particle activation studies which demonstrated significant performance and cost advantages over conventional bioconjugation chemistries. These included up to six times lower capture antibody usage, up to six times faster activation and improved assay performance. Capture antibodies can account for up to 35% of total assay costs.**
- **CLIA activated particle product development work completed to date has provided the foundation for the launch of AnteoTech's new CLIA Kit offering at ADLM 2026 in late July in Anaheim, California. The Kit combines magnetic beads sourced from selected suppliers with AnteoBind™ NXT and optimised activation protocols, supporting the Company's strategy to move further up the diagnostic value chain through higher-value combined optimised and performance-leading products.**
- **Successful completion of the Initial Work Program and agreement to progress to the next stage represents another important milestone towards establishing a broader joint product development collaboration in the CLIA market with well-established partners and supports AnteoTech's commercialisation strategy.**

[1] ASX Announcement on 3 March 2026: AnteoTech commences collaborative new immunoassay product development program

MERRILL GRAY, MANAGING DIRECTOR & CHIEF EXECUTIVE OFFICER OF ANTEOTECH COMMENTED:

"It is great that this initial collaborative CLIA product development work program has been completed successfully and on schedule. During program interactions I have seen the Life Sciences team strengthen AnteoTech's customer relationship. We have now agreed on the next steps with the large Life Sciences company, and these include in-house work from their side and support for our Kit launch, by way of bead supply".

"As we continue progressing this collaboration, we are looking forward to launching our new CLIA Kit offering at ADLM in California in late July 2026. This is an important strategic step for AnteoTech as it moves us further up the diagnostics value chain, evolving from supplying enabling chemicals to providing combined and optimised higher-value, ready-to-use products simplifying customer testing and adoption.

"Establishing demand for our new CLIA Kits in potential pilot markets is underway so we can develop detailed "go to market" plans. Pilot market entry will showcase what we have developed and create opportunities for future partnering collaborations and customer relationships to be built."

"Our Life Sciences team continues to advance several exciting medium term CLIA product developments that combine AnteoTech's expertise in advanced chemistry and materials science. These products have the potential to deliver further improvements in magnetic particle activation performance while reducing customer costs, and I look forward to updating the market on these initiatives in due course"

Overview of the in-vitro diagnostics market, the CLIA market and the role of activated particles

Figure 1 outlines the segments of the large global in-vitro diagnostics (IVD) immunoassay market in which AnteoTech currently participates and the segments targeted for future expansion, including the CLIA market.

The collaborative development program announced on 3 March 2026, together with the agreed next stage of work, specifically supports AnteoTech's strategy to enter the CLIA market. The CLIA market was valued as generating approximately **US$13 billion** in annual revenues in 2024 and is forecast to grow at approximately 6% CAGR through to 2029. Successful entry into this market would almost double the addressable immunoassay markets AnteoTech participates in and represents an important step in the Company's broader Life Sciences business's commercialisation strategy.



Figure 1: Overview of the global in vitro diagnostics (IVD) market and immunoassay segments

CLIAs have become a cornerstone technology in clinical diagnostics, enabling the detection and quantification of hormones, infectious disease markers, cardiac biomarkers and tumour markers. Their high sensitivity, broad dynamic range and compatibility with automated laboratory platforms have made them one of the fastest-growing immunoassay technologies globally.

Performance improvement and cost reduction are critical priorities within the CLIA market. Researchers seek improved assay sensitivity, specificity and ease of use, while laboratory managers and procurement teams increasingly focus on reducing reagent consumption, improving laboratory workflows and lowering overall assay costs.

AnteoTech's proprietary AnteoBind™ NXT surface chemistry addresses customers' needs by improving antibody orientation on activated magnetic particles, enhancing assay performance while significantly reducing antibody consumption, translating to lower manufacturing costs for diagnostic companies.

AnteoTech's broader Life Science strategy is to move further up the diagnostic value chain, evolving from a supplier of an enabling chemistry to a provider of higher-value products, including ready-to-use CLIA Kits, optimised activation protocols and more. This approach increases the Company's commercial relevance to customers while expanding the value captured from each customer relationship.

Association for Diagnostics & Laboratory Medicine (ADLM) Conference and Expo

AnteoTech will attend ADLM 2026 in Anaheim, California, between 26-30 July 2026, one of the world's leading diagnostics and laboratory medicine conferences, where the Company will launch its new CLIA Kit.

The kits are comprised of magnetic particles sourced from selected suppliers, AnteoBind™ NXT activation chemicals, the corresponding buffers and optimised particle activation protocols, providing customers with a ready-to-use solution designed to simplify implementation and improve assay performance.

The Company will also showcase its AnteoBind™ product portfolio in Lateral Flow, Luminex and ELISA applications, engaging with existing and prospective customers, distribution partners and potential commercial collaborators. Customer outreach is well underway, with meetings scheduled throughout the conference.

Pilot CLIA "Go to Market" Strategy

AnteoTech has commenced assessment of several potential market entry pathways for its CLIA Kits, including in relation to regional distribution partners, activated magnetic particle suppliers and contract kit assembly partners. Initial work is focused on identifying the most efficient commercial model, regional assembly options and customer channels capable of supporting scalable market entry.

The Company is leveraging relationships established through Austrade and its distribution partners in South Korea, Japan and India to evaluate regional opportunities and optimise its commercialisation strategy. As these assessments progress, AnteoTech expects to prioritise the most attractive market entry pathways and will provide further updates as they become available.

Details of the company AnteoTech is working with (Counterparty)

AnteoTech confirms that, at this stage of the commercial relationship, it does not consider the identity of the counterparty to be information that a reasonable person would expect to have a material effect on the price or value of the entity's securities.

AnteoTech confirms that this announcement contains all material information relevant to assessing the impact of the contract on the price or value of the entity's securities and is not misleading by omission.

The counterparty is a large global Life Sciences company with good standing and creditworthiness.

This announcement has been authorised for release by the Board of AnteoTech Ltd.

- ENDS –

Media and investor enquiries: +61 7 3219 0085 or investors@anteotech.com

Company and Partnering enquiries: Merrill Gray, MD/CEO, on +61 7 3219 0085

For further information, please check our website **www.anteotech.com.**

About AnteoTech - (ASX:ADO)

AnteoTech is a supplier of advanced chemical and material solutions to the battery materials and life sciences markets. We leverage our market leading binding chemistry platform technology to develop and commercialise solutions for our global customer base. From our patented high silicon anode cross linker product Anteo X™ to our ceramic coated separator product Anteo S™ to our next-generation high silicon anode formulations Ultranode™ 70, 95 and X our Advanced Battery Technology business is applying its world-leading engineering expertise to address the growing demand for high performance, low cost, sustainable materials within the global Lithium ion Battery market. Our Life Sciences business supplies advanced activation materials to leading developers and manufacturers of vaccines and diagnostic tests, through our AnteoBind™ suite of products. Our products deliver more sensitive and reproducible results and on incorporation in 'point of care' and immunoassay diagnostic tests, enable faster, more reliable and accurate test results wherever they are needed.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive our email alert service.

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regard to future events in respect to AnteoTech's business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.